[go: up one dir, main page]

MXPA03010201A - Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives. - Google Patents

Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives.

Info

Publication number
MXPA03010201A
MXPA03010201A MXPA03010201A MXPA03010201A MXPA03010201A MX PA03010201 A MXPA03010201 A MX PA03010201A MX PA03010201 A MXPA03010201 A MX PA03010201A MX PA03010201 A MXPA03010201 A MX PA03010201A MX PA03010201 A MXPA03010201 A MX PA03010201A
Authority
MX
Mexico
Prior art keywords
cyclohexane
pyridine
substituted
diamine derivatives
derivatives
Prior art date
Application number
MXPA03010201A
Other languages
Spanish (es)
Inventor
Barbara Heller
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of MXPA03010201A publication Critical patent/MXPA03010201A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/36—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)

Abstract

The invention relates to substituted 2-pyridine-cyclohexane-1,4-diamine derivatives, to a method for the production of said derivatives, to medicaments containing these compounds and to the use of substituted 2-pyridine-cyclohexane-1,4-diamine derivatives for the production of medicaments.
MXPA03010201A 2001-05-09 2002-05-08 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives. MXPA03010201A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10123163A DE10123163A1 (en) 2001-05-09 2001-05-09 Substituted cyclohexane-1,4-diamine derivatives
PCT/EP2002/005078 WO2002090330A1 (en) 2001-05-09 2002-05-08 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives

Publications (1)

Publication Number Publication Date
MXPA03010201A true MXPA03010201A (en) 2006-02-09

Family

ID=7684562

Family Applications (3)

Application Number Title Priority Date Filing Date
MXPA03010134A MXPA03010134A (en) 2001-05-09 2002-05-08 Substituted cyclohexane-1,4-diamine derivatives.
MXPA03010201A MXPA03010201A (en) 2001-05-09 2002-05-08 Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives.
MXPA03010195A MXPA03010195A (en) 2001-05-09 2002-05-09 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MXPA03010134A MXPA03010134A (en) 2001-05-09 2002-05-08 Substituted cyclohexane-1,4-diamine derivatives.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MXPA03010195A MXPA03010195A (en) 2001-05-09 2002-05-09 Substituted cyclohexan-1,4-diamine derivatives with constipating and peripheral analgesic properties.

Country Status (30)

Country Link
US (3) US6998409B2 (en)
EP (3) EP1385825B1 (en)
JP (3) JP2004528374A (en)
KR (2) KR100895778B1 (en)
CN (2) CN1533374B (en)
AR (1) AR035883A1 (en)
AT (2) ATE370120T1 (en)
AU (3) AU2002341195B2 (en)
BR (2) BR0209579A (en)
CA (3) CA2446461C (en)
CO (2) CO5700725A2 (en)
CY (2) CY1106468T1 (en)
CZ (2) CZ20033005A3 (en)
DE (3) DE10123163A1 (en)
DK (2) DK1392641T3 (en)
EC (2) ECSP034831A (en)
ES (2) ES2284876T3 (en)
HU (3) HU229288B1 (en)
IL (4) IL158784A0 (en)
MX (3) MXPA03010134A (en)
NO (2) NO328600B1 (en)
NZ (2) NZ529334A (en)
PE (1) PE20021094A1 (en)
PL (3) PL220595B1 (en)
PT (2) PT1392641E (en)
RU (2) RU2287523C2 (en)
SI (2) SI1385825T1 (en)
SK (2) SK287319B6 (en)
WO (3) WO2002090330A1 (en)
ZA (2) ZA200309521B (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10252650A1 (en) * 2002-11-11 2004-05-27 Grünenthal GmbH New 1,4-disubstituted cyclohexylamine derivatives, are opioid receptor like-receptor 1 receptor ligands useful e.g. for treating anxiety, depression, epilepsy, senile dementia, withdrawal symptoms or especially pain
DE10252665A1 (en) 2002-11-11 2004-06-03 Grünenthal GmbH 4-aminomethyl-1-aryl-cyclohexylamine derivatives
DE50312412D1 (en) 2002-11-12 2010-03-25 Gruenenthal Gmbh 4-hydroxymethyl-1-aryl-cyclohexylamin-derivative
JP4206382B2 (en) * 2002-11-19 2009-01-07 アキリオン ファーマシューティカルズ，インコーポレーテッド Substituted arylthioureas and related compounds; inhibitors of viral replication
US7026432B2 (en) 2003-08-12 2006-04-11 General Electric Company Electrically conductive compositions and method of manufacture thereof
US7354988B2 (en) 2003-08-12 2008-04-08 General Electric Company Electrically conductive compositions and method of manufacture thereof
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
US7309727B2 (en) 2003-09-29 2007-12-18 General Electric Company Conductive thermoplastic compositions, methods of manufacture and articles derived from such compositions
DE10360792A1 (en) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclic cyclohexane derivatives
DE10360793A1 (en) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclic cyclohexane derivatives
DE102004023522A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Substituted cyclohexyl-1,4-diamine derivatives
DE102004023507A1 (en) 2004-05-10 2005-12-01 Grünenthal GmbH Substituted cyclohexylacetic acid derivatives
DE102004023506A1 (en) * 2004-05-10 2005-12-01 Grünenthal GmbH Chain-extended substituted cyclohexyl-1,4-diamine derivatives
DE102004023635A1 (en) 2004-05-10 2006-04-13 Grünenthal GmbH Heteroaryl-substituted cyclohexyl-1,4-diamine derivatives
DE102004023632A1 (en) * 2004-05-10 2005-12-08 Grünenthal GmbH Substituted cyclohexylcarboxylic acid derivatives
DE102004023508A1 (en) * 2004-05-10 2005-12-08 Grünenthal GmbH Acid derivatives of substituted cyclohexyl-1,4-diamine
DE102004023501A1 (en) 2004-05-10 2005-12-01 Grünenthal GmbH Oxo-substituted cyclohexyl-1,4-diamine derivatives
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7462656B2 (en) 2005-02-15 2008-12-09 Sabic Innovative Plastics Ip B.V. Electrically conductive compositions and method of manufacture thereof
DE102005061428A1 (en) 2005-12-22 2007-08-16 Grünenthal GmbH Substituted cyclohexylmethyl derivatives
DE102006033109A1 (en) * 2006-07-18 2008-01-31 Grünenthal GmbH Substituted heteroaryl derivatives
DE102006033114A1 (en) 2006-07-18 2008-01-24 Grünenthal GmbH Spirocyclic azaindole derivatives
DE102006035787A1 (en) 2006-07-28 2008-03-13 Tesa Ag Process for punching non-tacky heat-activatable adhesives at room temperature
US20080194557A1 (en) * 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
US8003692B2 (en) * 2007-06-15 2011-08-23 Board Of Regents, The University Of Texas System Methods and compositions to inhibit edema factor and adenylyl cyclase
US20090215725A1 (en) * 2008-02-26 2009-08-27 Grunenthal Gmbh Substituted 4-aminocyclohexane derivatives
CA2719735A1 (en) * 2008-03-27 2009-10-01 Gruenenthal Gmbh Substituted 4-aminocyclohexane derivatives
ES2482108T3 (en) 2008-03-27 2014-08-01 Grünenthal GmbH Hydroxymethylcyclohexylamine
RU2515895C2 (en) 2008-03-27 2014-05-20 Грюненталь Гмбх Spiro(5,5)undecane derivatives
TWI450899B (en) 2008-03-27 2014-09-01 Substituted spirocyclic cyclohexane derivatives
US8357705B2 (en) * 2008-03-27 2013-01-22 Gruenenthal Gmbh Substituted cyclohexyldiamines
CL2009000733A1 (en) 2008-03-27 2009-05-15 Gruenenthal Chemie Compounds derived from (hetero) aryl-substituted cyclohexane, pharmaceutical composition containing said compound and its use as modulators of the µ-opioid receptor and the orl-1 receptor to treat pain, anxiety, depression, epilepsy, Alzheimer's, senile dementia, withdrawal symptoms, alcohol abuse.
PT2324013E (en) 2008-07-21 2012-12-24 Purdue Pharma Lp Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
KR101736218B1 (en) 2009-09-25 2017-05-16 오리존 지노믹스 에스.에이. Lysine Specific Demethylase-1 INHIBITORS THEIR USE
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
RU2599248C2 (en) 2010-04-19 2016-10-10 Оризон Дженомикс С.А. Lysin-specific demethylase-1 inhibitors and use thereof
EP3375775A1 (en) 2010-07-29 2018-09-19 Oryzon Genomics, S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
WO2012045883A1 (en) 2010-10-08 2012-04-12 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
JP6215212B2 (en) 2011-10-20 2017-10-18 オリゾン・ジェノミックス・ソシエダッド・アノニマＯｒｙｚｏｎ Ｇｅｎｏｍｉｃｓ Ｓ．Ａ． (Hetero) arylcyclopropylamine compounds as LSD1 inhibitors
CN103958474B (en) 2011-10-20 2017-03-08 奥莱松基因组股份有限公司 (miscellaneous) aryl cyclopropyl amines as LSD1 inhibitor
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
TWI773657B (en) 2015-12-18 2022-08-11 美商亞德利克斯公司 Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU172460B (en) * 1975-10-03 1978-09-28 Chinoin Gyogyszer Es Vegyeszet SPOSOB POLUCHENIA NOVYKH PROIZVODNYKH 5,6-DIGIDRO-3H-PIRIMIDIN-4-ONA
US4065573A (en) * 1976-06-03 1977-12-27 The Upjohn Company 4-Amino-4-phenylcyclohexanone ketal compositions and process of use
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US4447454A (en) * 1977-04-01 1984-05-08 The Upjohn Company Analgetic compounds, compositions and process of treatment
US5877277A (en) 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US4906655A (en) 1989-01-24 1990-03-06 Warner-Lambert Company Novel 1,2-cyclohexylaminoaryl amides useful as analgesic agents
US5153226A (en) 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
EP0524439A1 (en) * 1991-07-24 1993-01-27 F.Hoffmann-La Roche & Co. Aktiengesellschaft Novel cyclohexane and tetrahydropyran derivatives and antifungal compositions containing these derivatives
FR2687147A1 (en) 1992-02-11 1993-08-13 Union Pharma Scient Appl NOVEL ALPHA-AMINO N-PYRIDYL BENZENE PROPANAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US5620955A (en) 1993-06-18 1997-04-15 Peptide Technologies Corporation Bombesin receptor antagonists and uses thereof
GB9411099D0 (en) * 1994-06-03 1994-07-27 Wyeth John & Brother Ltd Piperazine derivatives
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
CA2203428A1 (en) 1995-08-21 1997-02-27 Philip Arthur Hipskind 2-acylaminopropanamides as growth hormone secretagogues
PL331710A1 (en) 1996-08-22 1999-08-02 Warner Lambert Co Antagonists of non-peptidic bombezinic receptors
AU1679099A (en) * 1998-01-19 1999-08-02 Pfizer Inc. 4-(2-keto-1-benzimidazolinyl)piperidine compounds as orl1-receptor agonists
US20020169101A1 (en) 1999-05-10 2002-11-14 Gonzalez Maria Isabel Treatment of sexual dysfunction
GB0006289D0 (en) 2000-03-15 2000-05-03 Smithkline Beecham Plc New use
GB0012240D0 (en) * 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
US20020028799A1 (en) 2000-07-06 2002-03-07 Naylor Alasdair Mark Treatment of male sexual dysfunction
US6991916B2 (en) 2000-07-14 2006-01-31 Pfizer Inc. Compounds for the treatment of sexual dysfunction
DE60135764D1 (en) * 2000-10-06 2008-10-23 Mitsubishi Tanabe Pharma Corp NITROGENIC, FIVE-GLASS RING COMPOUNDS
US20020055759A1 (en) 2000-11-06 2002-05-09 Shibuya Terry Y. Bioactive surgical suture
EP1349851A4 (en) 2000-11-16 2004-09-08 Smithkline Beecham Corp Compounds
BR0115364A (en) 2000-11-17 2003-09-23 Warner Lambert Co Treatment of sexual dysfunction
GB2369117A (en) 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
KR20040062416A (en) 2000-11-17 2004-07-07 워너-램버트 캄파니 엘엘씨 Treatment of Sexual Dysfunction Using Bombesin Antagonist
GB2369118A (en) 2000-11-17 2002-05-22 Warner Lambert Co Bombesin receptor antagonists
KR20030051843A (en) 2000-11-17 2003-06-25 워너-램버트 캄파니 엘엘씨 Treatment of Sexual Dysfunction
US20030119714A1 (en) 2000-12-15 2003-06-26 Naylor Alasdair Mark Treatment of male sexual dysfunction

Also Published As

Publication number Publication date
DK1392641T3 (en) 2007-07-16
MXPA03010134A (en) 2004-03-10
SI1385825T1 (en) 2008-02-29
ES2284876T3 (en) 2007-11-16
DE10123163A1 (en) 2003-01-16
PE20021094A1 (en) 2003-01-25
ECSP034831A (en) 2004-03-23
DE50210707D1 (en) 2007-09-27
JP2004528374A (en) 2004-09-16
PT1392641E (en) 2007-05-31
CN1533374B (en) 2013-08-21
ATE359260T1 (en) 2007-05-15
IL158784A (en) 2009-09-01
US7276518B2 (en) 2007-10-02
NZ529147A (en) 2006-10-27
US6998409B2 (en) 2006-02-14
PL212887B1 (en) 2012-12-31
RU2003134145A (en) 2005-05-20
PL366631A1 (en) 2005-02-07
SK287319B6 (en) 2010-07-07
EP1392641A1 (en) 2004-03-03
EP1385825A1 (en) 2004-02-04
SK286617B6 (en) 2009-02-05
RU2003134147A (en) 2005-05-20
CN1537100A (en) 2004-10-13
JP2005515959A (en) 2005-06-02
WO2002089783A1 (en) 2002-11-14
EP1392641B1 (en) 2007-04-11
CZ20033005A3 (en) 2004-03-17
HU228253B1 (en) 2013-02-28
ZA200309521B (en) 2004-09-28
ATE370120T1 (en) 2007-09-15
PL368851A1 (en) 2005-04-04
RU2287523C2 (en) 2006-11-20
WO2002090330A1 (en) 2002-11-14
DE50209929D1 (en) 2007-05-24
CY1108067T1 (en) 2014-02-12
AU2002341195B2 (en) 2007-01-04
CY1106468T1 (en) 2012-01-25
IL158782A (en) 2010-04-15
CO5700725A2 (en) 2006-11-30
CA2446461A1 (en) 2002-11-14
JP2004533439A (en) 2004-11-04
US20040162287A1 (en) 2004-08-19
IL158782A0 (en) 2004-05-12
HUP0400963A2 (en) 2004-08-30
NO328600B1 (en) 2010-03-29
BR0209579A (en) 2004-06-22
HK1070049A1 (en) 2005-06-10
MXPA03010195A (en) 2004-03-10
DK1385825T3 (en) 2007-11-05
CA2446461C (en) 2011-04-26
SI1392641T1 (en) 2007-10-31
KR100895778B1 (en) 2009-05-08
RU2321579C2 (en) 2008-04-10
EP1385493A1 (en) 2004-02-04
AR035883A1 (en) 2004-07-21
CA2446463A1 (en) 2002-11-14
ES2291486T3 (en) 2008-03-01
HUP0400888A2 (en) 2004-07-28
IL158784A0 (en) 2004-05-12
HUP0400989A2 (en) 2004-08-30
HK1062911A1 (en) 2004-12-03
KR20040002943A (en) 2004-01-07
ZA200309522B (en) 2005-02-23
ECSP034830A (en) 2004-03-23
NZ529334A (en) 2004-10-29
NO20034931L (en) 2004-01-02
HUP0400989A3 (en) 2011-08-29
CO5540300A2 (en) 2005-07-29
NO20034930D0 (en) 2003-11-05
PT1385825E (en) 2007-09-04
CN1533374A (en) 2004-09-29
HUP0400888A3 (en) 2008-03-28
EP1385825B1 (en) 2007-08-15
WO2002090317A1 (en) 2002-11-14
AU2002312883B2 (en) 2007-09-06
HU229288B1 (en) 2013-10-28
NO20034930L (en) 2004-01-05
BR0209580A (en) 2004-06-22
CA2446463C (en) 2010-07-13
AU2007202033A1 (en) 2007-05-24
US20040147741A1 (en) 2004-07-29
CZ20032995A3 (en) 2004-02-18
SK13792003A3 (en) 2004-06-08
PL366662A1 (en) 2005-02-07
KR20040017214A (en) 2004-02-26
PL220595B1 (en) 2015-11-30
CN1307158C (en) 2007-03-28
SK13782003A3 (en) 2004-04-06
AU2007202033B8 (en) 2010-03-04
NO326784B1 (en) 2009-02-16
NO20034931D0 (en) 2003-11-05
US20040229872A1 (en) 2004-11-18
AU2007202033B2 (en) 2010-02-04
CA2446735A1 (en) 2002-11-14

Similar Documents

Publication Publication Date Title
MXPA03010201A (en) Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives.
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
WO2003104473A3 (en) Galactosyl isomalt, method for production and use thereof
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
MXPA06007171A (en) Spirocyclic cyclohexane derivatives with affinity for the orl1-receptor.
GB0130341D0 (en) Compounds
WO2003080582A3 (en) Fredericamycin derivatives
WO2002053516A3 (en) N(phenylsulphonyl)glycine derivatives and their therapeutic use
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA03012013A (en) Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain.
PL364598A1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
WO2001010816A3 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
DE50202504D1 (en) NEW 4-AMINOFUROPYRIMIDINE AND ITS USE
WO2002030870A3 (en) Substituted c-cyclohexylmethylamine derivatives
WO2003037863A3 (en) Substituted indoles, method for production and use thereof for the inhibition of pain
WO2002010152A3 (en) Novel indole derivatives and their use as medicaments
MXPA04004090A (en) Substituted 1h-quinolin-2-one compounds.
WO2001049654A3 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
GB0229081D0 (en) Multifunctional cationic photoinitiators, their preparation and use
MXPA04000446A (en) Substituted 4-aminocyclohexanols.
TW200510323A (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
WO2004022542A3 (en) Substituted 1,2,3,4-tetrahydroquinoline derivatives
WO2001049651A3 (en) Aminomethyl-phenyl-cyclohexanone derivatives
MXPA04000272A (en) Substituted 4-aminocyclohexanol derivatives.

Legal Events

Date Code Title Description
FG Grant or registration